( (CODE <begin_1468-6708-3-3>))

( (NP (DT The) (NN problem)))

( (S (NP-SBJ (NP (CD Three) (VBN published))
	     (CODE <bracket>)
	     (CODE {COM:footnote_indexes_omitted})
	     (CODE <$$bracket>)
	     (CC and)
	     (NP (NP (CD one)
		     (VP (ADVP-TMP (RB recently))
			 (VBN presented)
			 (NP (-NONE- *))))
		 (CODE <bracket>)
		 (CODE {COM:footnote_index_omitted})
		 (CODE <$$bracket>)
		 (JJ randomized)
		 (ADJP (NN placebo) (HYPH -) (VBN controlled))
		 (JJ clinical)
		 (NN trial)))
     (VP (VBP have)
	 (ADVP-MNR (RB unequivocally))
	 (VP (VBN demonstrated)
	     (SBAR (IN that)
		   (S (NP-SBJ (NP (NML (NML (NN 3-Hydroxy-3-methylgluatryl) (NN coenzyme) (NN A))
				       (CODE -LRB-)
				       (NML (NN HMG) (NN CoA)))
				  (CODE -RRB-)
				  (JJ reductase)
				  (NNS inhibitors)
				  (CODE -LRB-))
			      (NP (NNS statins)))
		      (CODE -RRB-)
		      (VP (VBP reduce)
			  (NP (NP (DT the) (NN morbidity) (CC and) (NN mortality))
			      (VP (VBN associated)
				  (NP (-NONE- *))
				  (PP-CLR (IN with)
					  (NP (JJ coronary) (NN disease))))))))))
     (. .)))

( (S (NP-SBJ (DT These) (NNS trials))
     (VP (VBD found)
	 (SBAR (IN that)
	       (S (SBAR-TMP (WHADVP-1 (WRB when))
			    (S (NP-SBJ-2 (-NONE- *PRO*-3))
			       (VP (VBN compared)
				   (NP (-NONE- *-2))
				   (PP-CLR (IN with)
					   (NP (NN placebo)))
				   (ADVP-TMP (-NONE- *T*-1)))))
		  (, ,)
		  (NP-SBJ-3 (NNS statins))
		  (ADVP (RB significantly))
		  (VP (VBD reduced)
		      (NP (NP (DT the) (NN incidence))
			  (PP (IN of)
			      (NP (NP (NN death))
				  (, ,)
				  (NP (JJ myocardial) (NN infarction))
				  (, ,)
				  (NP (JJ unstable) (NN angina))
				  (, ,)
				  (NP (ADJP (JJ percutaneous) (CC and) (JJ surgical))
				      (JJ coronary)
				      (NN revascularization))
				  (, ,)
				  (CC and)
				  (NP (NN stroke)))))
		      (PP (IN in)
			  (NP (NP (NNS persons))
			      (PP (IN with)
				  (NP (JJ stable) (JJ coronary) (NN disease)))))))))
     (. .)))

( (S (SBAR-PRP (IN Because)
	       (S (NP-SBJ-1 (NP (NNS patients))
			    (SBAR (WHNP-2 (WP who))
				  (S (NP-SBJ (-NONE- *T*-2))
				     (VP (VBD had)
					 (VP (VBN experienced)
					     (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome))
					     (PP-TMP (IN within)
						     (NP (NP (QP (NP (NP (CD three))
								     (PP (IN to)
									 (NP (CD six)))))
							     (NNS months))
							 (PP (IN of)
							     (NP (NN enrollment))))))))))
		  (VP (VBD were)
		      (VP (VBN excluded)
			  (NP (-NONE- *-1))))))
     (, ,)
     (NP-SBJ (DT these) (NNS trials))
     (VP (VBD did)
	 (RB not)
	 (VP (VB assess)
	     (NP (NP (DT the) (NN effect))
		 (PP (IN of)
		     (NP (ADJP (NN lipid) (HYPH -) (NN lowering))
			 (NN therapy)))
		 (PP (IN on)
		     (NP (JJ adverse) (JJ cardiovascular) (NNS events)))
		 (PP (IN in)
		     (NP (NP (DT those))
			 (PP (IN with)
			     (NP (ADJP (RB recently) (JJ unstable))
				 (JJ coronary)
				 (NN disease))))))))
     (. .)))

( (S (SBAR-SBJ (IN Whether)
	       (S (NP-SBJ-1 (ADJP (NN lipid) (HYPH -) (NN lowering))
			    (NN therapy))
		  (VP (MD would)
		      (VP (VB provide)
			  (NP (JJ incremental) (NN benefit))
			  (SBAR-ADV (IN if)
				    (S (NP-SBJ-2 (-NONE- *PRO*-1))
				       (VP (VBN initiated)
					   (NP (-NONE- *-2))
					   (ADVP-TMP (RB immediately))
					   (PP-TMP (VBG following)
						   (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome))))))))))
     (VP (VBZ is)
	 (NP-PRD (DT an) (JJ important) (NN issue))
	 (SBAR-ADV (IN as)
		   (S (NP-SBJ (NP (DT the) (NN risk))
			      (PP (IN of)
				  (NP (DT a) (JJ recurrent) (JJ adverse) (JJ cardiac) (NNS events))))
		      (VP (VBZ is)
			  (ADJP-PRD (ADJP (RB much) (JJR greater))
				    (PP (-NONE- *ICH*-3)))
			  (PP (IN in)
			      (NP (NP (NNS patients))
				  (PP (IN with)
				      (NP (JJ unstable) (JJ coronary) (NN disease)))))
			  (PP-3 (IN than)
				(PP (IN in)
				    (NP (DT the) (JJ stable) (NN setting))))))))
     (. .)))

( (S (NP-SBJ-1 (NP (DT The)
		   (NML (NML (JJ Myocardial) (NN Ischemia) (NN Reduction))
			(PP (IN with)
			    (NP (JJ Aggressive) (NN Cholesterol) (NN Lowering)))
			(CODE -LRB-)
			(PRN (NP (NN MIRACL))))
		   (CODE -RRB-)
		   (NN trial)))
     (VP (VBD set)
	 (PRT (RP out))
	 (S-PRP (NP-SBJ (-NONE- *PRO*-1))
		(VP (TO to)
		    (VP (VB answer)
			(NP (DT this) (NN question))))))
     (. .)))

( (NP (DT The) (NN answer) (. ?)))

( (S (NP-SBJ (NN MIRACL))
     (VP (VP (VBD enrolled)
	     (NP (CD 3,086) (NNS patients))
	     (PP-TMP (IN within)
		     (NP (NP (QP (CD 24) (SYM -) (CD 96))
			     (NNS hours)
			     (CODE -LRB-)
			     (JJ mean)
			     (CD 63)
			     (NNS hours))
			 (PP (CODE -RRB-)
			     (IN of)
			     (NP (NP (NN admission))
				 (PP (IN for)
				     (NP (NP (JJ unstable) (NN angina))
					 (CC or)
					 (NP (DT a) (NN non-Q-wave))
					 (NP (JJ myocardial) (NN infarction)))))))))
	 (CC and)
	 (VP (VBD randomized)
	     (NP (PRP them))
	     (PP-TMP (IN to)
		     (NP (NP (CD 16) (NNS weeks))
			 (PP (IN of)
			     (NP (NN atorvastatin))))))
	 (NP (NP (CD 80) (NNS mg) (CC or) (NN placebo))
	     (NP (ADVP (RB once) (RB daily))
		 (NP (CODE <bracket>) (CD 5)))))
     (CODE <$$bracket>)
     (. .)))

( (S (NP-SBJ (DT The) (JJ major) (NN exclusion) (NNS criteria))
     (VP (VBD were)
	 (: :)
	 (NP-PRD (NP (JJ total)
		     (NN cholesterol)
		     (NN level)
		     (QP (JJR greater) (IN than) (CD 270) (NNS mg) (SYM $$) (NNS dL)))
		 (, ;)
		 (NP (NP (NN Q-wave) (JJ myocardial) (NN infarction))
		     (PP (PP (IN on)
			     (NP (NN admission)))
			 (CC or)
			 (PP (IN during)
			     (NP (DT the) (JJ previous) (NN month)))))
		 (, ;)
		 (CC and)
		 (, ,)
		 (NP (NP (JJ coronary) (NN revascularization))
		     (UCP (PP (IN in)
			      (NP (NP (DT the) (NNS months))
				  (PP (IN before)
				      (NP (NN admission)))))
			  (, ,)
			  (PP (IN during)
			      (NP (DT the) (NN index) (NN hospitalization)))
			  (CC or)
			  (VP (VBN anticipated)
			      (NP (-NONE- *))
			      (PP-TMP (VBG following)
				      (NP (NN hospital) (NN discharge))))))))
     (. .)))

( (S (NP-SBJ (DT The) (JJ primary) (NN efficacy) (NN endpoint))
     (VP (VBD was)
	 (NP-PRD (NP (DT a) (NN composite))
		 (PP (IN of)
		     (NP (NP (NN death))
			 (, ,)
			 (NP (JJ non-fatal) (JJ myocardial) (NN infarction))
			 (, ,)
			 (NP (VBN resuscitated) (JJ sudden) (JJ cardiac) (NN death))
			 (CC or)
			 (NP (NP (JJ emergent) (NN rehospitalization))
			     (PP (IN for)
				 (NP (VBG worsening) (JJ symptomatic) (JJ myocardial) (NN ischemia))))))))
     (. .)))

( (S (NP-SBJ (JJ Secondary) (NNS endpoints))
     (VP (VBD included)
	 (NP (NP (NN stroke))
	     (, ,)
	     (NP (VBG worsening) (NN heart) (NN failure))
	     (, ,)
	     (NP (NP (NN need))
		 (PP (IN for)
		     (NP (JJ coronary) (NN revascularization))))
	     (CC and)
	     (NP (NP (NN change))
		 (PP (IN in)
		     (NP (NN lipid) (NNS levels)))
		 (PP (IN throughout)
		     (NP (DT the) (NN study))))))
     (. .)))

( (S (S (PP (IN On)
	    (ADJP (JJ average)))
	(, ,)
	(NP-SBJ (NNS patients))
	(VP (VBD were)
	    (NP-PRD (NP (CD 65) (NNS years))
		    (PP (IN of)
			(NP (NN age))))))
     (, ,)
     (S (S (NP-SBJ=1 (QP (RB approximately) (CD 65))
		     (NN %))
	   (VP (VBD were)
	       (NP-PRD=2 (NNS men))))
	(, ,)
	(S (NP-SBJ=1 (CD 86) (NN %))
	   (ADJP-PRD=2 (JJ Caucasian))))
     (CC and)
     (S (NP-SBJ (DT the)
		(JJ mean)
		(NN baseline)
		(NML (NML (JJ low) (NN density))
		     (NN lipoprotein)
		     (CODE -LRB-)
		     (PRN (NP (NN LDL))))
		(CODE -RRB-)
		(NN cholesterol)
		(NN level))
	(VP (VBD was)
	    (NP-PRD (CD 124) (NNS mg) (SYM $$) (NNS dL))))
     (. .)))

( (S (NP-SBJ-1 (NN Atorvastatin) (NN treatment))
     (VP (VBD was)
	 (VP (VBN associated)
	     (NP (-NONE- *-1))
	     (PP-CLR (IN with)
		     (NP (NP (DT a)
			     (NML (CD 2.6) (NN %))
			     (JJ absolute)
			     (NN reduction))
			 (PP (IN in)
			     (NP (NP (DT the) (NN risk))
				 (PP (IN of)
				     (NP (DT the) (JJ primary) (NN endpoint)))))))
	     (CODE -LRB-)
	     (FRAG (NP (NP (CD 14.8) (NN %))
		       (PP (IN vs.)
			   (NP (CD 17.4) (NN %))))
		   (, ;)
		   (NP (NN RR) (JJ relative) (NN risk))
		   (CODE <bracket>)
		   (NN RR)
		   (CODE <$$bracket>)
		   (CD 0.84)
		   (, ,)
		   (NP (NML (CD 95) (NN %))
		       (NN confidence)
		       (NN interval))
		   (CODE <bracket>)
		   (FRAG (NP (NN CI))
			 (CODE <$$bracket>)
			 (NP (QP (CD 0.70) (SYM -) (CD 1.00))))
		   (, ,)
		   (S (NP-SBJ (NN p))
		      (VP (SYM =)
			  (NP-PRD (CD 0.048)))))))
     (CODE -RRB-)
     (. .)))

( (S (NP-SBJ-1 (DT This) (NN reduction))
     (VP (VBD was)
	 (ADVP-MNR (RB primarily))
	 (VP (VBN driven)
	     (NP (-NONE- *-1))
	     (PP (IN by)
		 (NP-LGS (NP (DT the)
			     (NML (CD 2.2) (NN %))
			     (JJ absolute)
			     (NN reduction))
			 (PP (IN in)
			     (NP (NP (NN incidence))
				 (PP (IN of)
				     (NP (NP (JJ emergent) (NN rehospitalization))
					 (PP (IN for)
					     (NP (JJ symptomatic) (JJ myocardial) (NN ischemia)))))))))))
     (CODE -LRB-)
     (FRAG (NP (NP (CD 6.2) (NN %))
	       (PP (IN vs.)
		   (NP (CD 8.4) (NN %))))
	   (, ;)
	   (NP (NN RR) (CD 0.74))
	   (, ,)
	   (NP (NML (CD 95) (NN %))
	       (NN CI))
	   (QP (CD 0.57) (HYPH -) (CD 0.95))
	   (, ,)
	   (S (NP-SBJ (NN p))
	      (VP (SYM =)
		  (NP-PRD (CD 0.02)))))
     (CODE -RRB-)
     (. .)))

( (S (NP-SBJ (NP (DT The) (NN risk))
	     (PP (IN of)
		 (NP (NP (NN death))
		     (, ,)
		     (NP (JJ nonfatal) (JJ myocardial) (NN infarction))
		     (CC and)
		     (NP (VBN resuscitated) (JJ sudden) (JJ cardiac) (NN death)))))
     (VP (VBD were)
	 (RB each)
	 (ADJP-PRD (RB no) (JJ different))
	 (PP (IN between)
	     (NP (DT the) (CD two) (NNS groups))))
     (. .)))

( (S (SBAR-TMP (IN While)
	       (S (NP-SBJ (EX there))
		  (VP (VBD were)
		      (NP-PRD (NP (DT no) (JJ significant) (NNS differences))
			      (PP (IN in)
				  (NP (NP (DT the) (NN incidence))
				      (PP (IN of)
					  (NP (NP (VBG worsening) (NN heart) (NN failure))
					      (CC or)
					      (NP (NP (NN need))
						  (PP (IN for)
						      (NP (JJ coronary) (NN revascularization))))))))))))
     (NP-SBJ (, ,) (NN atorvastatin))
     (VP (VBD did)
	 (VP (VB reduce)
	     (NP (NP (DT the) (NN incidence))
		 (PP (IN of)
		     (NP (ADJP (JJ fatal) (CC or) (JJ non-fatal))
			 (NN stroke))))
	     (PP-EXT (IN by)
		     (NP (NP (CD 0.8) (NN %))
			 (NP (NP (CODE -LRB-) (CD 0.8) (NN %))
			     (PP (IN vs.)
				 (NP (CD 1.6) (NN %) (, ;) (NN RR) (CD 0.50))))
			 (NP (, ,) (CD 95) (NN %) (NN CI) (CD 0.26))
			 (NP (SYM -) (CD 0.99) (, ,) (NN p) (SYM =) (CD 0.045))))))
     (CODE -RRB-)
     (. .)))

( (S (NP-SBJ (NN Atorvastatin))
     (ADVP (RB also))
     (ADVP-MNR (RB significantly))
     (VP (VP (VBD reduced)
	     (NP (NML (NML (UCP (JJ total) (CC and) (NN LDL))
			   (NN cholesterol))
		      (CC and)
		      (NN triglyceride))
		 (NNS levels)))
	 (CC but)
	 (VP (VBD did)
	     (RB not)
	     (ADVP (RB significantly))
	     (VP (VB change)
		 (NP (NML (NML (JJ high) (NN density))
			  (NN lipoprotein))
		     (CODE -LRB-)
		     (PRN (NP (NN HDL)))
		     (CODE -RRB-)
		     (NN cholesterol))
		 (PP-TMP (IN by)
			 (NP (CD 16) (NNS weeks))))))
     (. .)))

( (S (PP-TMP (IN By)
	     (NP (CD 16) (NNS weeks)))
     (, ,)
     (NP-SBJ (DT the) (VBN adjusted) (JJ mean) (NN LDL) (NN cholesterol))
     (VP (VP (VBD decreased)
	     (PP-EXT (IN to)
		     (NP (NML (CD 72) (NNS mg))
			 (SYM $$)
			 (NNS dL)))
	     (PP (IN in)
		 (NP (ADJP (NN atorvastatin) (HYPH -) (VBN treated))
		     (NNS patients))))
	 (CC but)
	 (VP (VBD increased)
	     (PP-EXT (IN to)
		     (NP (NML (CD 135) (NNS mg))
			 (SYM $$)
			 (NNS dL)))
	     (PP (IN among)
		 (NP (ADJP (NN placebo) (HYPH -) (VBN treated))
		     (NNS patients)))))
     (. .)))

( (S (NP-SBJ (DT No) (JJ serious) (JJ adverse) (NNS events))
     (VP (VBD occurred)
	 (PP (IN as)
	     (NP (NP (DT the) (NN result))
		 (PP (IN of)
		     (NP (NP (NN treatment))
			 (PP (IN with)
			     (NP (NN atorvastatin)))))))
	 (, ,)
	 (SBAR-ADV (IN although)
		   (S (NP-SBJ (NP (JJ reversible)
				  (NML (NN liver) (NN transaminase))
				  (NN elevation))
			      (RRC (NP (NP (NML (QP (JJR more) (IN than) (CD three))
						(NNS times))
					   (DT the)
					   (JJ upper)
					   (NN limit))
				       (PP (IN of)
					   (NP (JJ normal))))))
		      (VP (VBD occurred)
			  (PP (IN in)
			      (NP (QP (CD 2.5) (NN %) (IN of))
				  (ADJP (NN atorvastatin) (HYPH -) (VBN treated))))
			  (PP (IN versus)
			      (NP (QP (CD 0.6) (NN %) (IN of))
				  (ADJP (NN placebo) (HYPH -) (VBN treated))
				  (NNS patients)))
			  (CODE -LRB-)
			  (S-ADV (NP-SBJ (NN p))
				 (NP-PRD (SYM <) (CD 0.001)))))))
     (CODE -RRB-)
     (. .)))

( (NP (DT The) (JJ MIRACuLous)))

( (S (NP-SBJ (NP (DT The)
		 (NML (NN efficacy) (CC and) (NN safety))
		 (NNS findings))
	     (PP (IN from)
		 (NP (NN MIRACL))))
     (VP (VBD were)
	 (ADJP-PRD (JJ unique))
	 (PP-PRP (IN for)
		 (NP (NP (DT a) (NN number))
		     (PP (IN of)
			 (NP (NNS reasons))))))
     (. .)))

( (S (SBAR-ADV (IN Although)
	       (S (NP-SBJ-1 (NML (NN lipid) (HYPH -) (NN lowering))
			    (NN therapy))
		  (VP (VBD was)
		      (VP (VBN associated)
			  (NP (-NONE- *-1))
			  (PP-CLR (IN with)
				  (NP (DT a)
				      (ADJP (RB significantly) (JJR lower))
				      (NN mortality)))
			  (SBAR-TMP (WHADVP-2 (WRB when))
				    (S (NP-SBJ-3 (-NONE- *PRO*-1))
				       (VP (VBN initiated)
					   (NP (-NONE- *-3))
					   (ADVP-TMP (-NONE- *T*-2))
					   (ADVP-TMP (RB early))
					   (PP-TMP (IN after)
						   (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))
					   (PP (IN in)
					       (NP (CD two) (JJ large) (JJ observational) (NNS studies))))))))))
     (CODE <bracket>)
     (CODE {COM:footnote_indexicals_omitted})
     (CODE <$$bracket>)
     (, ,)
     (NP-SBJ (NN MIRACL))
     (VP (VBD was)
	 (NP-PRD (NP (DT the) (JJ first) (VBN randomized) (NN trial))
		 (SBAR (WHNP-4 (-NONE- 0))
		       (S (NP-SBJ (-NONE- *T*-4))
			  (VP (TO to)
			      (VP (VB suggest)
				  (SBAR (IN that)
					(S (NP-SBJ (NNS statins))
					   (VP (VBP confer)
					       (NP (JJ clinical) (NNS benefits))
					       (PP (IN in)
						   (NP (DT this) (NN setting))))))))))))
     (. .)))

( (S (S (NP-SBJ (PRP It))
	(VP (VBD was)
	    (ADVP (RB also))
	    (NP-PRD (NP (DT the) (JJ first) (NN trial))
		    (SBAR (WHNP-1 (-NONE- 0))
			  (S (NP-SBJ (-NONE- *T*-1))
			     (VP (TO to)
				 (VP (VB identify)
				     (NP (NP (DT a)
					     (NML (JJ short) (HYPH -) (NN term))
					     (CODE -LRB-)
					     (PRN (FW ie)
						  (, ,)
						  (PP-TMP (IN within)
							  (NP (CD 16) (NNS weeks))))
					     (CODE -RRB-)
					     (JJ clinical)
					     (NN benefit))
					 (PP (IN from)
					     (NP (NN statin) (NN therapy)))))))))))
     (, ;)
     (S (PP (IN in)
	    (NP (JJ previous)
		(NML (JJ secondary) (NN prevention))
		(NNS trials)))
	(, ,)
	(NP-SBJ (NP (DT the) (NN benefit))
		(PP (IN of)
		    (NP (NN statin) (NN therapy))))
	(VP (VBD was)
	    (RB not)
	    (ADJP-PRD (JJ evident))
	    (PP-TMP (IN for)
		    (NP (QP (QP (CD one))
			    (PP (IN to)
				(NP (CD two))))
			(NNS years)))))
     (. .)))

( (S (CC And)
     (, ,)
     (SBAR-ADV (IN while)
	       (S (NP-SBJ-1 (NML (JJ clinical) (NN trial))
			    (NN safety)
			    (NNS endpoints))
		  (VP (MD may)
		      (VP (VB be)
			  (VP (VBN considered)
			      (S (NP-SBJ (-NONE- *-1))
				 (ADJP-PRD (RBR less) (JJ glamorous))))))))
     (, ,)
     (NP-SBJ (NP (NN MIRACL) (POS 's))
	     (ADJP (RBS most) (JJ important))
	     (NN contribution))
     (VP (MD may)
	 (VP (VB have)
	     (VP (VBN been)
		 (SBAR-PRD (IN that)
			   (S (NP-SBJ-2 (NML (JJ high) (HYPH -) (NN dose))
					(NN statin)
					(NN therapy))
			      (VP (VBD was)
				  (RB not)
				  (VP (VBN associated)
				      (NP (-NONE- *-2))
				      (PP-CLR (IN with)
					      (NP (JJ serious) (NN harm)))
				      (, ,)
				      (PP (IN despite)
					  (NP (NP (PRP$ its) (NN use))
					      (PP (IN in)
						  (NP (DT the) (JJ unstable) (NN setting))))))))))))
     (. .)))

( (S (NP-SBJ (RBR Earlier)
	     (NML (JJ secondary) (NN prevention))
	     (NN statin)
	     (NNS trials))
     (VP (VBD had)
	 (VP (VBN excluded)
	     (NP (NP (NNS patients))
		 (PP (IN with)
		     (NP (JJ unstable) (JJ coronary) (NNS syndromes))))
	     (PP-PRP (ADVP (RB largely))
		     (IN out)
		     (PP (IN of)
			 (NP (NP (JJ theoretical) (NN concern))
			     (SBAR (IN that)
				   (S (NP-SBJ (NP (ADJP (NN statin) (HYPH -) (VBN mediated))
						  (NNS reductions))
					      (PP (IN in)
						  (NP (NML (JJ vascular)
							   (NML (NML (JJ smooth) (NN muscle))
								(NN cell)))
						      (NN proliferation))))
				      (VP (MD might)
					  (VP (VB destabilize)
					      (NP (VBG healing) (NN plaque)))))))))))
     (. .)))

( (S (SBAR-NOM-SBJ (IN That)
		   (S (NP-SBJ (DT no) (NN harm))
		      (VP (VBD resulted)
			  (PP (IN from)
			      (NP (DT this) (JJ aggressive) (NN treatment) (NN strategy))))))
     (VP (MD should)
	 (VP (VP (VB allay)
		 (NP (JJ theoretical) (NNS fears)))
	     (CC and)
	     (PP-MNR (IN by)
		     (S-NOM (NP-SBJ (-NONE- *PRO*))
			    (VP (VBG doing)
				(ADVP-PRD (RB so)))))
	     (VP (VB remove)
		 (NP (NP (DT a) (JJ major) (NN obstacle))
		     (PP (IN to)
			 (NP (NP (DT the) (NN inpatient) (NN initiation))
			     (PP (IN of)
				 (NP (NML (NN lipid) (HYPH -) (NN lowing))
				     (NN therapy))))))
		 (PP-TMP (IN after)
			 (NP (JJ coronary) (NNS events))))))
     (. .)))

( (NP (DT The)
      (ADJP (RB not) (RB so) (JJ MIRACuLous))))

( (S (PP (IN Despite)
	 (NP (DT these)
	     (ADJP (JJ unique) (CC and) (JJ important))
	     (NNS findings)))
     (, ,)
     (NP-SBJ (EX there))
     (VP (VBD were)
	 (NP-PRD (NP (QP (DT a) (NN number) (IN of))
		     (JJ inherent)
		     (NN study)
		     (NNS limitations))
		 (ADJP (ADJP (JJ worth))
		       (S (NP-SBJ (-NONE- *PRO*))
			  (VP (VBG noting))))))
     (. .)))

( (S (ADVP (RB First) (CC and) (RB foremost))
     (, ,)
     (NP-SBJ-1 (NP (DT the) (NN possibility))
	       (PP (IN of)
		   (NP (DT a)
		       (NML (JJ null) (NN treatment))
		       (NN effect))))
     (VP (MD can)
	 (RB not)
	 (VP (VB be)
	     (VP (VBN ignored)
		 (NP (-NONE- *-1))
		 (S-ADV (NP-SBJ-2 (-NONE- *PRO*))
			(VP (VBN given)
			    (NP (-NONE- *-2))
			    (NP (NP (NP (DT the) (JJ wide) (NN confidence) (NNS intervals))
				    (CODE -LRB-)
				    (CC and)
				    (NP (NP (ADVP (RB hence))
					    (ADJP (RB marginally) (JJ significant))
					    (NN p)
					    (NN value))
					(PP (IN of)
					    (NP (CD 0.048)))))
				(CODE -RRB-)
				(PP (IN for)
				    (NP (NP (DT the) (NN effect))
					(PP (IN of)
					    (NP (NP (NN atorvastatin))
						(PP (IN on)
						    (NP (DT the)
							(NML (JJ primary) (NN efficacy))
							(NN endpoint)))))))))))))
     (. .)))

( (S (ADVP (RB Furthermore))
     (, ,)
     (SBAR-ADV (IN while)
	       (S (NP-SBJ (NP (DT the) (NN number))
			  (PP (IN of)
			      (NP (NP (NNS patients))
				  (VP (VBN lost)
				      (NP (-NONE- *))
				      (PP (IN to)
					  (NP (GW follow) (NN up)))))))
		  (VP (VBD was)
		      (ADJP-PRD (JJ small)))))
     (, ,)
     (SBAR-ADV (IN if)
	       (S (NP-SBJ (JJ adverse) (NNS events))
		  (VP (VBD had)
		      (VP (VBN occurred))
		      (PP (IN in)
			  (NP (NP (DT those))
			      (VP (VP (VBN treated)
				      (NP (-NONE- *))
				      (PP (IN with)
					  (NP=1 (NN atorvastatin)))
				      (CODE -LRB-)
				      (PRN=2 (S (NP-SBJ (NN n))
						(SYM =)
						(NP-PRD (CD 2)))))
				  (CODE -RRB-)
				  (CC but)
				  (VP (RB not)
				      (NP=1 (NN placebo))
				      (CODE -LRB-)
				      (PRN=2 (S (NP-SBJ (NN n))
						(SYM =)
						(NP-PRD (CD 8)))))))))))
     (CODE -RRB-)
     (, ,)
     (NP-SBJ (DT the) (JJ overall) (NN trial) (NNS results))
     (VP (MD may)
	 (VP (VB have)
	     (VP (VBN been)
		 (ADJP-PRD (ADJP (JJ neutral))
			   (PP (IN rather)
			       (IN than)
			       (ADJP (JJ positive))))
		 (. .))))))

( (S (NP-SBJ (NP (DT The) (NNS types))
	     (PP (IN of)
		 (NP (NP (NNS events))
		     (VP (VBN prevented)
			 (NP (-NONE- *))
			 (PP (IN in)
			     (NP (NN MIRACL)))))))
     (VP (VBP are)
	 (ADVP (RB also))
	 (ADJP-PRD (ADJP (JJ worth))
		   (S (NP-SBJ (-NONE- *PRO*))
		      (VP (VBG noting)))))
     (. .)))

( (S (SBAR-TMP (IN While)
	       (S (NP-SBJ (NP (NN rehospitalization))
			  (PP (IN for)
			      (NP (JJ recurrent) (JJ myocardial) (NN ischemia))))
		  (VP (VBZ is)
		      (NP-PRD (NP (DT an) (JJ important) (NN determinant))
			      (PP (IN of)
				  (NP (NP (NP (NN quality))
					  (PP (IN of)
					      (NP (NN life))))
				      (CC and)
				      (NP (NML (NN health) (NN care))
					  (NNS costs))))))))
     (, ,)
     (NP-SBJ-1 (NP (JJ other) (JJ important) (NNS endpoints))
	       (NP (-NONE- *ICH*-2)))
     (VP (VBD were)
	 (RB not)
	 (ADVP (RB significantly))
	 (VP (VBN affected)
	     (NP (-NONE- *-1))
	     (CODE -LRB-)
	     (NP-2 (FW eg)
		   (, ,)
		   (NP (NN death)
		       (, ,)
		       (NP (JJ myocardial) (NN infarction)))
		   (, ,)
		   (NP (VBN resuscitated) (JJ sudden) (JJ cardiac) (NN death))
		   (, ,)
		   (NP (VBG worsening) (NN heart) (NN failure))
		   (, ,)
		   (NP (NP (NN need))
		       (PP (IN for)
			   (NP (JJ coronary) (NN revascularization))))
		   (, ,)
		   (NP (FW etc)))))
     (CODE -RRB-)
     (. .)))

( (S (NP-SBJ (NP (DT The) (NN question))
	     (PP (IN of)
		 (SBAR (IN whether)
		       (S (NP-SBJ-1 (NNS statins))
			  (VP (MD can)
			      (VP (VB prevent)
				  (NP (UCP (DT these) (CC and) (JJ other))
				      (JJ adverse)
				      (NNS events))
				  (SBAR-TMP (WHADVP-2 (WRB when))
					    (S (NP-SBJ-3 (-NONE- *PRO*-1))
					       (VP (VBN initiated)
						   (NP (-NONE- *-3))
						   (PP-TMP (ADVP-TMP (RB soon))
							   (IN after)
							   (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))
						   (ADVP-TMP (-NONE- *T*-2)))))))))))
     (VP (MD will)
	 (VP (VB require)
	     (NP (JJR further) (NN study))))
     (. .)))

( (S (NP-SBJ (NP (DT The) (JJ short) (NN duration))
	     (PP (IN of)
		 (NP (NN follow-up))))
     (VP (VBZ is)
	 (ADJP-PRD (RB also) (RB particularly) (JJ troubling)))
     (. .)))

( (S (SBAR-ADV (IN While)
	       (S (NP-SBJ (NP (PRP it))
			  (SBAR (-NONE- *EXP*-1)))
		  (VP (VBZ is)
		      (ADJP-PRD (JJ impressive))
		      (SBAR-1 (IN that)
			      (S (NP-SBJ-2 (DT a) (JJ clinical) (NN benefit))
				 (VP (VBD was)
				     (VP (VBN realized)
					 (NP (-NONE- *-2))
					 (PP-TMP (IN after)
						 (NP (NP (QP (RB only) (CD 16))
							 (NNS weeks))
						     (PP (IN of)
							 (NP (NN statin) (NN therapy))))))))))))
     (, ,)
     (NP-SBJ (NP (DT the) (VBN increased) (NN risk))
	     (PP (IN of)
		 (NP (JJ adverse) (JJ clinical) (NNS events))))
     (VP (VBZ persists)
	 (PP-TMP (IN throughout)
		 (NP (NP (DT the) (NN year))
		     (VP (VBG following)
			 (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome))))))
     (. .)))

( (S (PP (IN Without)
	 (NP (RBR longer) (JJ clinical) (GW follow) (NN up)))
     (, ,)
     (NP-SBJ (NP (PRP it))
	     (S (-NONE- *EXP*-1)))
     (VP (VBZ is)
	 (RB not)
	 (ADJP-PRD (JJ possible))
	 (S-TPC-1 (NP-SBJ (-NONE- *PRO*))
		  (VP (TO to)
		      (VP (VB assess)
			  (NP (NP (NP (NP (DT the)
					  (ADJP (JJ intermediate) (HYPH -) (NN term))
					  (NN effect))
				      (CODE -LRB-)
				      (PRN (SBAR-ADV (IN if)
						     (FRAG (NP (DT any))))))
				  (CODE -RRB-)
				  (PP (IN of)
				      (NP (NN atorvastatin))))
			      (PP (IN on)
				  (NP (NP (JJ hard) (NNS endpoints))
				      (PP (IN such)
					  (IN as)
					  (NP (NP (NN death))
					      (CC or)
					      (NP (JJ myocardial) (NN infarction)))))))))))
     (. .)))

( (S (S-SBJ (NP-SBJ (-NONE- *PRO*))
	    (VP (TO To)
		(VP (VB do)
		    (ADVP-PRD (RB so)))))
     (VP (MD would)
	 (VP (VB be)
	     (ADJP-PRD (JJ critical))
	     (PP (IN in)
		 (NP (NP (NN light))
		     (PP (IN of)
			 (NP (NP (DT the) (NN lack))
			     (PP (IN of)
				 (NP (NP (NN effect))
				     (PP (IN on)
					 (NP (DT these) (JJ important) (NNS endpoints)))))
			     (PP (IN at)
				 (NP (CD 16) (NNS weeks)))))))))
     (. .)))

( (S (ADVP (RB Unfortunately))
     (, ,)
     (NP-SBJ (DT no) (JJ late) (JJ clinical) (GW follow) (NN up))
     (VP (VBZ is)
	 (ADJP-PRD (VBN planned)))
     (. .)))

( (S (NP-SBJ (EX There))
     (VP (VBD were)
	 (ADVP (RB also))
	 (NP-PRD (NP (QP (DT a) (NN number) (IN of))
		     (NNS limitations))
		 (SBAR (WHNP-1 (WDT that))
		       (S (NP-SBJ (-NONE- *T*-1))
			  (VP (MD may)
			      (VP (VB have)
				  (VP (VBN hampered)
				      (NP (NP (DT the) (NN study) (POS 's))
					  (NN generalizability)))))))))
     (. .)))

( (S (ADVP-TMP (RB First))
     (, ,)
     (NP-SBJ-1 (NP (NNS patients))
	       (SBAR (SBAR (WHNP-2 (WP who))
			   (S (NP-SBJ (-NONE- *T*-2))
			      (VP (VBD underwent)
				  (NP (JJ recent) (NN revascularization)))))
		     (CC or)
		     (SBAR (WHPP-3 (IN in)
				   (WHNP (WP whom)))
			   (S (NP-SBJ-4 (PRP it))
			      (VP (VBD was)
				  (VP (VBN planned)
				      (NP (-NONE- *-4))
				      (PP (-NONE- *T*-3))))))))
     (VP (VBD were)
	 (VP (VBN excluded)
	     (NP (-NONE- *-1))))
     (. .)))

( (S (ADVP (RB Specifically))
     (, ,)
     (NP-SBJ (NP (NNS patients))
	     (SBAR (WHNP-1 (WP who))
		   (S (NP-SBJ (-NONE- *T*-1))
		      (VP (VBD underwent)
			  (NP (NML (NML (JJ percutaneous)
					(JJ transluminal)
					(JJ coronary)
					(NN angioplasty)
					(CODE -LRB-)
					(PRN (NML (NN PTCA))))
				   (CODE -RRB-)
				   (CC or)
				   (NML (NML (NML (JJ coronary) (NN artery))
					     (NN bypass))
					(NN graft)
					(CODE -LRB-)
					(PRN (NML (NN CABG)))))
			      (CODE -RRB-)
			      (NN surgery))
			  (PP-TMP (IN within)
				  (NP (DT the)
				      (JJ previous)
				      (QP (CD three) (CC or) (CD six))
				      (NNS months)))
			  (ADVP (RB respectively))))))
     (VP (VBD were)
	 (RB not)
	 (ADJP-PRD (ADJP (JJ eligible))
		   (PP (IN for)
		       (NP (NN inclusion)))))
     (. .)))

( (S (NP-SBJ (DT The) (NNS investigators))
     (VP (VBD reasoned)
	 (SBAR (SBAR (IN that)
		     (S (NP-SBJ-1 (NP (JJ recurrent) (JJ ischemic) (NNS events))
				  (PP (IN in)
				      (NP (DT this) (NN population))))
			(VP (VBD were)
			    (ADJP-PRD (ADJP (JJ likely))
				      (S (NP-SBJ (-NONE- *-1))
					 (VP (TO to)
					     (VP (VB result)
						 (PP-CLR (IN from)
							 (NP (NP (NN restenosis))
							     (CC or)
							     (NP (NML (NN bypass) (NN graft))
								 (NN closure)))))))))))
	       (CC and)
	       (SBAR (IN that)
		     (S (NP-SBJ (NNS statins))
			(VP (MD would)
			    (VP (VB be)
				(ADJP-PRD (ADJP (RBR less) (JJ likely))
					  (S (NP-SBJ (-NONE- *PRO*))
					     (VP (TO to)
						 (VP (VB affect)
						     (NP (DT these) (NNS processes))))))))))))
     (CODE {TEXT:footnote_markers_omitted})
     (. .)))

( (S (NP-SBJ (NP (RB Nevertheless) (, ,) (DT a) (NN number))
	     (PP (IN of)
		 (NP (NNS trials))))
     (VP (VBP have)
	 (VP (VBN established)
	     (NP (NP (DT the) (NNS benefits))
		 (PP (IN of)
		     (NP (NN statin) (NN therapy))))
	     (PP-MNR (ADVP (RB early))
		     (IN after)
		     (NP (JJ coronary)
			 (NN revascularization)
			 (QP (CODE <bracket>) (CD 9) (CD 10) (CD 11))))))
     (CODE <$$bracket>)
     (. .)))

( (S (S (ADVP (RB Furthermore))
	(, ,)
	(NP-SBJ (NP (DT a) (NN number))
		(PP (IN of)
		    (NP (JJ recent) (NNS trials))))
	(VP (VBP have)
	    (VP (VBN suggested)
		(SBAR (IN that)
		      (S (NP-SBJ (NP (NML (JJR higher) (NN risk))
				     (NNS patients))
				 (PP (IN with)
				     (NP (NML (NN non-ST) (NN elevation))
					 (JJ acute)
					 (JJ coronary)
					 (NNS syndromes))))
			 (VP (VBP fair)
			     (ADVP-MNR (RBR better))
			     (SBAR-TMP (WHADVP-1 (WRB when))
				       (S (NP-SBJ-2 (DT an) (JJ early) (JJ invasive) (NN strategy))
					  (VP (VBZ is)
					      (VP (VBN applied)
						  (NP (-NONE- *-2))
						  (ADVP-TMP (-NONE- *T*-1))))))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (CC and)
     (S (NP-SBJ (NP (PRP it))
		(SBAR (-NONE- *EXP*-3)))
	(VP (VBZ is)
	    (RB not)
	    (ADJP-PRD (JJ uncommon))
	    (SBAR-3 (IN for)
		    (S (NP-SBJ-4 (NNS patients))
		       (VP (TO to)
			   (VP (VB be)
			       (VP (VBN treated)
				   (NP (-NONE- *-4))
				   (PP-MNR (IN in)
					   (NP (DT this) (NN fashion))))))))))
     (. .)))

( (S (ADVP-TMP (RBR Second))
     (, ,)
     (NP-SBJ (NP (NNS patients))
	     (PP (IN with)
		 (NP (NN Q-wave) (JJ myocardial) (NN infarction))))
     (VP (VBD were)
	 (RB not)
	 (ADJP-PRD (ADJP (JJ eligible))
		   (PP (IN for)
		       (NP (NN enrollment))))
	 (SBAR-PRP (IN because)
		   (S (NP-SBJ-1 (NP (PRP it))
				(SBAR (-NONE- *EXP*-2)))
		      (VP (VBD was)
			  (VP (VBN felt)
			      (NP (-NONE- *-1))
			      (SBAR-2 (IN that)
				      (S (NP-SBJ (NNS statins))
					 (VP (MD would)
					     (RB not)
					     (VP (VB influence)
						 (NP (NP (DT the) (NN development))
						     (PP (IN of)
							 (NP (NP (JJ important) (JJ prognostic) (NNS determinants))
							     (PP (IN such)
								 (IN as)
								 (NP (NP (ADJP (JJ left) (JJ ventricular))
									 (JJ systolic)
									 (NN dysfunction))
								     (, ,)
								     (NP (JJ ventricular) (NNS arrhythmias))
								     (CC or)
								     (NP (JJ mechanical) (NNS complications))))))))))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (ADVP (RB Nevertheless))
     (, ,)
     (NP-SBJ (NP (NNS patients))
	     (SBAR (WHNP-1 (WP who))
		   (S (NP-SBJ (-NONE- *T*-1))
		      (VP (VBP develop)
			  (NP (JJ electrocardiographic) (NNS Q-waves))))))
     (VP (VBP represent)
	 (NP (NP (DT a) (JJ substantial) (NN proportion))
	     (PP (IN of)
		 (NP (NP (DT all) (NNS patients))
		     (PP (IN with)
			 (NP (JJ myocardial) (NN infarction)))))))
     (. .)))

( (S (S (SBAR-ADV (IN While)
		  (S (NP-SBJ (NP (PRP$ their)
				 (NML (JJ short) (HYPH -) (NN term))
				 (NN risk))
			     (PP (VBG following)
				 (NP (NN hospital) (NN discharge))))
		     (VP (VBZ is)
			 (ADJP-PRD (ADJP (JJR lower))
				   (ADJP (ADJP (JJ relative))
					 (PP (IN to)
					     (NP (NP (DT those))
						 (PP (IN with)
						     (NP (DT a) (NN non-Q-wave) (JJ myocardial) (NN infarction))))))))))
	(, ,)
	(NP-SBJ (PRP it))
	(VP (VBZ is)
	    (ADVP (RB still))
	    (ADJP-PRD (ADJP (RB much) (JJR greater))
		      (PP (IN than)
			  (PP (IN in)
			      (NP (NP (NNS patients))
				  (PP (IN with)
				      (NP (JJ stable) (JJ coronary) (NN disease)))))))))
     (, ,)
     (CC and)
     (S (NP-SBJ (NP (DT the) (NN need))
		(PP (IN for)
		    (NP (JJ secondary) (NN prevention)))
		(PP (IN in)
		    (NP (DT this) (NN population))))
	(VP (VBZ is)
	    (ADJP-PRD (RB equally) (JJ important))))
     (. .)))

( (S (ADVP-TMP (RB Third))
     (, ,)
     (PP (IN despite)
	 (NP (NP (DT the)
		 (NML (JJ high) (NN risk))
		 (NN nature))
	     (PP (IN of)
		 (NP (VBN enrolled) (NNS patients)))
	     (CODE -LRB-)
	     (PRN (NP (FW ie)
		      (, ,)
		      (NP (NN electrocardiogram)
			  (CODE <bracket>)
			  (PRN (NP (NN ECG)))
			  (CODE <$$bracket>)
			  (NNS changes))
		      (CONJP (CC and) (SYM $$) (CC or))
		      (NP (NP (JJ other) (JJ objective) (NN evidence))
			  (PP (IN of)
			      (NP (NN ischemia))))))))
     (CODE -RRB-)
     (, ,)
     (NP-SBJ (NP (DT the) (NN rate))
	     (PP (IN of)
		 (NP (NML (NML (NN platelet) (NN glycoprotein))
			  (NML (NN IIb) (SYM $$) (NN IIIa))
			  (NN inhibitor))
		     (NN utilization))))
     (VP (VBD was)
	 (ADJP-PRD (RB quite)
		   (JJ low)
		   (CODE -LRB-)
		   (QP (CD 1.1) (NN %))))
     (CODE -RRB-)
     (. .)))

( (S (NP-SBJ-1 (JJ Such) (NN therapy))
     (VP (VP (VBZ appears)
	     (S (NP-SBJ (-NONE- *-1))
		(VP (TO to)
		    (VP (VB be)
			(ADJP-PRD (NN cost) (JJ effective))
			(CODE {COM:footnote_indexical_omitted})
			(, ,)
			(PP (ADVP (RB especially))
			    (IN among)
			    (NP (NML (JJ high) (NN risk))
				(NNS patients)))))))
	 (CC and)
	 (VP (VBZ is)
	     (VP (VBN recommended)
		 (NP (-NONE- *-1))
		 (PP (IN under)
		     (NP (JJ current)
			 (NML (NML (NML (NNP American) (NNP College))
				   (PP (IN of)
				       (NP (NNP Cardiology))))
			      (SYM $$)
			      (NML (NNP American) (NNP Heart) (NNP Association)))
			 (NNS guidelines))))))
     (CODE {COM:footnote_indexical_omitted})
     (. .)))

( (S (ADVP-TMP (RB Fourth))
     (, ,)
     (NP-SBJ (NP (PRP it))
	     (S (-NONE- *EXP*-1)))
     (VP (MD may)
	 (RB not)
	 (VP (VB be)
	     (ADJP-PRD (JJ possible))
	     (S-1 (NP-SBJ (-NONE- *PRO*))
		  (VP (TO to)
		      (VP (VB ascertain)
			  (SBAR (IN whether)
				(S (NP-SBJ (DT these) (NNS findings))
				   (VP (VB apply)
				       (PP (IN to)
					   (NP (NP (DT all) (NNS patients))
					       (PP (IN with)
						   (NP (JJ recent) (JJ acute) (JJ coronary) (NNS syndromes)))))
				       (ADVP (RB regardless)
					     (PP (IN of)
						 (NP (NN baseline) (NN lipid) (NNS levels))))))))))))
     (. .)))

( (S (NP-SBJ (NP (DT The) (JJ small) (NN difference))
	     (PP (IN in)
		 (NP (NP (NN number))
		     (PP (IN of)
			 (NP (JJ primary) (NN endpoint) (NNS events)))))
	     (PP (IN between)
		 (NP (NML (NN atorvastatin) (CC and) (NN placebo))
		     (NNS groups))))
     (VP (VBP make)
	 (S (NP-SBJ (NP (PRP it))
		    (S (-NONE- *EXP*-1)))
	    (ADJP-PRD (JJ difficult))
	    (S-1 (NP-SBJ (-NONE- *PRO*))
		 (VP (TO to)
		     (VP (VB dissect)
			 (NP (NP (DT the) (NN relationship))
			     (PP (IN between)
				 (NP (NP (NN baseline) (NN lipid) (NNS levels))
				     (CC and)
				     (NP (NN treatment) (NN effect)))))
			 (ADVP-MNR (RBR further)))))))
     (. .)))

( (S (ADVP (RB Consequently))
     (, ,)
     (NP-SBJ (NP (PRP it))
	     (SBAR (-NONE- *EXP*-1)))
     (VP (VBZ remains)
	 (ADJP-PRD (JJ uncertain))
	 (SBAR-1 (IN whether)
		 (S (NP-SBJ (PRP one))
		    (VP (MD can)
			(VP (VB extrapolate)
			    (NP (DT the) (NN MIRACL) (NN trial) (NNS results))
			    (PP (IN to)
				(NP (NP (DT those))
				    (SBAR (SBAR (WHNP-2 (WP who))
						(S (NP-SBJ (-NONE- *T*-2))
						   (VP (VBP undergo)
						       (NP (JJ coronary) (NN revascularization))
						       (PP-TMP (ADVP (RB shortly))
							       (IN before)
							       (CC or)
							       (IN after)
							       (NP (DT a) (JJ coronary) (NN event))))))
					  (, ,)
					  (SBAR (WHNP-3 (WP who))
						(S (NP-SBJ (-NONE- *T*-3))
						   (VP (VBP present)
						       (PP (IN with)
							   (NP (DT a) (NN Q-wave) (JJ myocardial) (NN infarction))))))
					  (, ,)
					  (SBAR (WHNP-4 (WP who))
						(S (NP-SBJ-5 (-NONE- *T*-4))
						   (VP (VBP are)
						       (VP (VBN treated)
							   (NP (-NONE- *-5))
							   (PP-CLR (IN with)
								   (NP (NML (NN platelet) (NN glycoprotein))
								       (NML (NN IIb) (SYM $$) (NN IIIa))
								       (NNS inhibitors)))))))
					  (, ,)
					  (CC or)
					  (SBAR (WHNP-6 (WP who))
						(S (NP-SBJ (-NONE- *T*-6))
						   (VP (VBP have)
						       (NP (ADJP (RB relatively) (JJ low))
							   (NN admission)
							   (NML (NN LDL) (NN cholesterol))
							   (NNS levels)))))))))))))
     (. .)))

( (NP (NP (NN Time))
      (SBAR (WHNP-1 (-NONE- 0))
	    (S (NP-SBJ (-NONE- *PRO*))
	       (VP (TO to)
		   (VP (VB change)
		       (NP (JJ current) (NN practice))
		       (NP-TMP (-NONE- *T*-1))))))))

( (S (SBAR-ADV (IN Although)
	       (S (NP-SBJ (NP (NN MIRACL))
			  (CC and)
			  (NP (DT the) (CD two) (JJ aforementioned) (NN cohort) (NNS studies)))
		  (VP (VBP suggest)
		      (SBAR (IN that)
			    (S (NP-SBJ-1 (NML (NN lipid) (HYPH -) (NN lowering))
					 (NNS agents))
			       (VP (VBP exert)
				   (NP (ADJP (JJ short) (HYPH -) (NN term))
				       (JJ clinical)
				       (NNS benefits))
				   (SBAR-TMP (WHADVP-2 (WRB when))
					     (S (NP-SBJ-3 (-NONE- *PRO*-1))
						(VP (VBN initiated)
						    (NP (-NONE- *-3))
						    (ADVP-TMP (RB soon))
						    (PP-TMP (IN after)
							    (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))
						    (ADVP-TMP (-NONE- *T*-2)))))))))))
     (, ,)
     (NP-SBJ (DT this))
     (VP (VBZ remains)
	 (NP-PRD (DT an) (JJ open) (NN question)))
     (. .)))

( (S (S (SBAR-ADV (ADVP (RB Even))
		  (IN if)
		  (S (NP-SBJ-1 (DT these) (NNS findings))
		     (VP (VBP are)
			 (RB not)
			 (VP (VBN confirmed)
			     (NP (-NONE- *-1))
			     (PP-TMP (IN after)
				     (NP (JJR further) (NN study)))))))
	(, ,)
	(NP-SBJ (PRP one))
	(VP (MD could)
	    (ADVP-TMP (RB still))
	    (VP (VB make)
		(NP (NP (DT a) (JJ compelling) (NN argument))
		    (SBAR (IN that)
			  (S (NP-SBJ-2 (NML (NN lipid) (HYPH -) (NN lowering))
				       (NN therapy))
			     (CODE -LRB-)
			     (S-ADV (NP-SBJ (-NONE- *PRO*))
				    (VP (VBG barring)
					(NP (NNS contraindications))))
			     (CODE -RRB-)
			     (VP (MD should)
				 (VP (VB be)
				     (VP (VBN initiated)
					 (NP (-NONE- *-2))
					 (ADVP (ADVP-TMP (RB early))
					       (CC and)
					       (ADVP-MNR (RB universally)))
					 (PP (IN in)
					     (NP (NP (NNS patients))
						 (SBAR (WHNP-3 (WP who))
						       (S (NP-SBJ (-NONE- *T*-3))
							  (VP (VBP present)
							      (PP (IN with)
								  (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))))))))))))))))
     (: :)
     (S (LST (RB First))
	(, ,)
	(NP-SBJ (NP (DT the)
		    (ADJP (JJ long) (HYPH -) (NN term))
		    (NN safety)
		    (CC and)
		    (NN effectiveness))
		(PP (IN of)
		    (NP (NNS statins)))
		(PP (IN for)
		    (NP (NP (DT the) (JJ secondary) (NN prevention))
			(PP (IN of)
			    (NP (JJ stable) (JJ coronary) (NN disease))))))
	(VP (VBZ is)
	    (ADVP-MNR (RB well))
	    (HYPH -)
	    (ADJP-PRD (VBN established))))
     (CODE <bracket>)
     (CODE {COM:footnote_indexicals_omitted})
     (CODE <$$bracket>)
     (, ;)
     (S (LST (RB Second))
	(, ,)
	(SBAR-MNR (IN as)
		  (S (NP-SBJ (-NONE- *PRO*))
		     (VP (VBN evidenced)
			 (PP (IN by)
			     (NP-LGS (NN MIRACL))))))
	(, ,)
	(NP-SBJ-4 (DT these) (NNS agents))
	(VP (VBP are)
	    (ADJP-PRD (JJ safe))
	    (SBAR-TMP (WHADVP-5 (WRB when))
		      (S (NP-SBJ-6 (-NONE- *PRO*-4))
			 (VP (VBN initiated)
			     (NP (-NONE- *-6))
			     (PP-TMP (IN at)
				     (NP (NP (DT the) (NN time))
					 (PP (IN of)
					     (NP (NP (NN hospitalization))
						 (PP (IN for)
						     (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))))))
			     (ADVP-TMP (-NONE- *T*-5)))))))
     (, ;)
     (S (LST (RB Third))
	(, ,)
	(NP-SBJ-7 (NP (DT the)
		      (NML (PP (IN in)
			       (HYPH -)
			       (NP (NN hospital))))
		      (NN initiation))
		  (PP (IN of)
		      (NP (NML (NN lipid) (HYPH -) (NN lowering))
			  (NN therapy))))
	(VP (VBZ appears)
	    (S (NP-SBJ (-NONE- *-7))
	       (VP (TO to)
		   (VP (VB promote)
		       (NP (NP (JJR greater)
			       (ADJP (JJ long) (HYPH -) (NN term))
			       (NN utilization))
			   (PP (IN of)
			       (NP (DT these) (NNS agents)))))))))
     (CODE <bracket>)
     (CODE {COM:footnote_indexicals_omitted})
     (CODE <$$bracket>)
     (. .)))

( (S (S (ADVP (RB Finally))
	(, ,)
	(SBAR-ADV (IN although)
		  (S (NP-SBJ (NN lipid) (NNS levels))
		     (VP (MD may)
			 (VP (VB be)
			     (ADJP-PRD (JJ unreliable))
			     (PP (IN in)
				 (NP (NP (DT the) (NN setting))
				     (PP (IN of)
					 (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))))
			     (CODE -LRB-)
			     (PP (VBG excepting)
				 (NP (NML (NML (NN total) (SYM :) (NN HDL))
					  (CC and)
					  (NML (NN LDL) (SYM :) (NN HDL)))
				     (NN cholesterol)
				     (NNS ratios)))))))
	(CODE {COM:footnote_indexicals_omitted})
	(CODE -RRB-)
	(NP-SBJ-1 (NP (DT the) (JJ overwhelming) (NN majority))
		  (PP (IN of)
		      (NP (NP (NNS patients))
			  (PP (IN with)
			      (NP (JJ coronary) (NN disease))))))
	(VP (MD will)
	    (ADVP-TMP (RB ultimately))
	    (VP (VB require)
		(NP (ADJP (CC both) (JJ pharmacologic) (CC and) (JJ non-pharmacologic))
		    (ADJP (NN lipid) (HYPH -) (NN lowering))
		    (NNS interventions))
		(S-PRP (NP-SBJ (-NONE- *PRO*-1))
		       (VP (TO to)
			   (VP (VB attain)
			       (NP (JJ recommended) (NN cholesterol) (NNS targets))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (, ;)
     (S (NP-SBJ (JJR newer) (NNS guidelines))
	(VP (VBP are)
	    (ADJP-PRD (ADVP (RB even) (RBR more))
		      (JJ stringent))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (ADVP (RB Furthermore))
     (, ,)
     (NP-SBJ (NP (NNS data))
	     (PP (IN from)
		 (NP (DT the)
		     (ADJP (RB recently) (VBN presented))
		     (NML (NNP Heart) (NNP Protection))
		     (NNP Study))))
     (VP (VBP suggest)
	 (SBAR (IN that)
	       (S (NP-SBJ (JJ clinical) (NNS benefits))
		  (VP (MD may)
		      (VP (VB accrue)
			  (ADVP-MNR (ADVP (RB independent))
				    (PP (IN of)
					(NP (NN baseline) (NN cholesterol) (NN level)))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (ADVP (RB Thus))
     (, ,)
     (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*))
		   (VP (TO to)
		       (VP (VB withhold)
			   (NP (NML (NN lipid) (HYPH -) (NN lowering))
			       (NN therapy))
			   (PP (IN from)
			       (NP (NP (NNS patients))
				   (SBAR (WHNP-1 (WP who))
					 (S (NP-SBJ (-NONE- *T*-1))
					    (VP (VBP present)
						(PP (IN with)
						    (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))))))))))
	(VP (MD would)
	    (VP (VB be)
		(S-PRD (NP-SBJ (-NONE- *PRO*))
		       (VP (TO to)
			   (VP (VB accept)
			       (NP (DT the) (FW status) (FW quo))))))))
     (, ,)
     (CC and)
     (S (PP-TMP (IN to)
		(NP (NN date)))
	(NP-SBJ (NP (PRP$ our) (NNS efforts))
		(PP (IN at)
		    (NP (NN cholesterol) (NN lowering)))
		(PP (IN in)
		    (NP (DT the) (JJ secondary) (NN prevention) (NN setting))))
	(VP (VBP have)
	    (VP (VBN been)
		(ADJP-PRD (JJ dismal)))))
     (CODE {COM:footnote_indexical_omitted})
     (. .)))

( (ADVP-TMP (NP (JJR More) (NNS MIRACLes))
	    (RB ahead)
	    (. ?)))

( (S (NP-SBJ (NP (DT The) (NN ascertainment) (CC and) (NN quantification))
	     (PP (IN of)
		 (NP (NP (DT any) (JJ incremental) (NN benefit))
		     (VP (VBN conferred)
			 (NP (-NONE- *))
			 (PP (IN by)
			     (NP-LGS (NP (NN statin) (NN therapy))
				     (VP (VBN initiated)
					 (NP (-NONE- *))
					 (ADVP-TMP (RB early))
					 (PP-TMP (IN after)
						 (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome))))))))))
     (VP (MD will)
	 (VP (VB require)
	     (NP (NN confirmation))))
     (. .)))

( (S (NP-SBJ (EX There))
     (VP (VBZ is)
	 (ADVP (RB currently))
	 (NP-PRD (NP (NP (QP (RB only) (CD one))
			 (JJ ongoing)
			 (JJ randomized)
			 (ADJP (NN placebo) (HYPH -) (VBN controlled))
			 (NN trial))
		     (PP (IN of)
			 (NP (NP (JJ early))
			     (PP (IN versus)
				 (NP (VBN delayed) (NN statin) (NN therapy))))))
		 (NP (-NONE- *ICH*-1)))
	 (PP (IN in)
	     (NP (DT this) (NN setting)))
	 (, ,)
	 (NP-1 (NNP A-2-Z)
	       (CODE -LRB-)
	       (PRN (NP (NP (NNP Aggrastat))
			(PP (IN to)
			    (NP (NNP Zocor)))
			(, ,)
			(PRN (NP (NNP Merck)))))))
     (CODE -RRB-)
     (CODE <bracket>)
     (CD 29)
     (CODE <$$bracket>)
     (. .)))

( (S (NP-SBJ (DT The) (NNP A-2-Z) (NN study))
     (VP (VBZ is)
	 (VP (VBG evaluating)
	     (NP (NP (DT the) (NN efficacy))
		 (PP (IN of)
		     (NP (NP (NP (JJ early) (NN treatment))
			     (PP (IN with)
				 (NP (NN simvastatin)))
			     (PP (IN in)
				 (NP (NP (CD 4,500) (NNS patients))
				     (VP (VBG following)
					 (NP (NP (DT an) (NN episode))
					     (PP (IN of)
						 (NP (JJ unstable) (NN angina))))))))
			 (CC or)
			 (NP (DT a) (JJ non-Q) (NN wave))
			 (NP (JJ myocardial) (NN infarction)))))))
     (. .)))

( (S (PP-TMP (IN In)
	     (NP (DT the) (JJ first) (CD four) (NNS months)))
     (, ,)
     (NP-SBJ-1 (NNS patients))
     (VP (MD will)
	 (VP (VB be)
	     (VP (VBN randomized)
		 (NP (-NONE- *-1))
		 (PP (IN to)
		     (NP (NP (NP (NN simvastatin))
			     (ADVP-TMP (NP (CD 40) (NNS mg))
				       (RB daily)))
			 (CC or)
			 (NP (NN placebo)))))))
     (. .)))

( (S (S (ADVP-TMP (RB Thereafter))
	(, ,)
	(NP-SBJ=1 (NP (DT those) (NNS patients))
		  (VP (VBN treated)
		      (NP (-NONE- *))
		      (PP (IN with)
			  (NP (NN simvastatin)))
		      (PP-TMP (IN in)
			      (NP (DT the) (JJ first) (NN phase)))))
	(VP (MD will)
	    (VP (VB receive)
		(NP=2 (NML (CD 80) (NNS mg) (IN of))
		      (NN simvastatin))
		(ADVP-TMP=3 (RB daily)))))
     (CC and)
     (S (NP-SBJ=1 (NP (DT those))
		  (VP (VBN treated)
		      (NP (-NONE- *))
		      (PP (IN with)
			  (NP (NN placebo)))))
	(, ,)
	(NP=2 (NML (CD 40) (NNS mg) (IN of))
	      (NN simvastatin))
	(ADVP-TMP=3 (RB daily)))
     (. .)))

( (S (NP-SBJ (DT The) (JJ primary) (JJ composite) (NN endpoint))
     (VP (VBZ is)
	 (NP-PRD (NP (DT the) (NN occurrence))
		 (PP (IN of)
		     (NP (NP (JJ cardiovascular) (NN death))
			 (, ,)
			 (NP (JJ non-fatal) (JJ myocardial) (NN infarction))
			 (, ,)
			 (CC or)
			 (NP (NP (NN rehospitalization))
			     (PP (IN for)
				 (NP (DT an)
				     (JJ acute)
				     (JJ coronary)
				     (NN syndrome)
				     (CODE -LRB-)
				     (PRN (NP (NN ACS)))))
			     (CODE -RRB-)
			     (PP (IN at)
				 (NP (CD one) (NN year))))))))
     (. .)))

( (S (SBAR-ADV (IN If)
	       (S (NP-SBJ (NNP A-2-Z))
		  (VP (VBZ demonstrates)
		      (NP (NP (JJ significant) (NNS reductions))
			  (PP (IN in)
			      (NP (NP (DT the) (NN incidence))
				  (PP (IN of)
				      (NP (JJ adverse) (NNS events)))
				  (PP (IN during)
				      (NP (DT the)
					  (QP (JJ first) (CD four))
					  (NNS months)))))))))
     (, ,)
     (NP-SBJ (PRP it))
     (VP (MD would)
	 (VP (VB suggest)
	     (NP (NP (DT an) (JJ incremental) (JJ clinical) (NN benefit))
		 (PP (IN from)
		     (S-NOM (NP-SBJ (-NONE- *PRO*))
			    (VP (VBG initiating)
				(NP (DT these) (NNS agents))
				(ADVP-TMP (RB early))
				(PP-TMP (IN after)
					(NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))))))))
     (. .)))

( (S (SBAR-ADV (IN If)
	       (S (NP-SBJ (NNS benefits))
		  (VP (VP (VBP accrue))
		      (, ,)
		      (CC but)
		      (VP (VBP do)
			  (ADVP-PRD (RB so))
			  (ADVP-TMP (RBR later))
			  (PP-TMP (IN during)
				  (NP (GW follow) (NN up)))))))
     (, ,)
     (NP-SBJ (NP (PRP it))
	     (S (-NONE- *EXP*-1)))
     (VP (MD would)
	 (VP (VB be)
	     (ADJP-PRD (JJ difficult))
	     (S-TPC-1 (NP-SBJ (-NONE- *PRO*))
		      (VP (TO to)
			  (VP (VB discriminate)
			      (PP (IN between)
				  (NP (NP (DT the) (NNS effects))
				      (PP (IN of)
					  (NP (ADJP (ADJP (RBR more) (JJ aggressive))
						    (PP (IN vs.)
							(ADJP (JJR earlier))))
					      (NML (NN lipid) (NN lowering))
					      (NN therapy))))))))))
     (. .)))

( (S (NP-SBJ (DT The)
	     (NML (NML (NNP Pravastatin) (CC or) (NNP Atorvastatin))
		  (NML (NN Evaluation) (CC and) (NN Infection))
		  (NN Therapy)
		  (CODE -LRB-)
		  (PRN (NP-TTL (VB PROVE) (PRP IT)))
		  (CODE -RRB-))
	     (NN trial))
     (VP (VBZ is)
	 (VP (VP (VBG looking)
		 (PP-CLR (IN at)
			 (NP (CD 4,000) (NNS patients)))
		 (PP-TMP (IN within)
			 (NP (NP (CD 10) (NNS days))
			     (PP (IN of)
				 (NP (DT an) (JJ acute) (JJ coronary) (NN syndrome))))))
	     (CC and)
	     (VP (VBG randomizing)
		 (NP (PRP them))
		 (PP (IN to)
		     (NP (CC either)
			 (NP (NN pravastatin)
			     (PRN (NP (CD 40) (NNS mg))))
			 (CC or)
			 (NP (NN atorvastatin))
			 (PRN (NP (CD 80) (NNS mg)))
			 (ADVP-TMP (RB daily)))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (NP-SBJ-1 (NNS Patients))
     (VP (MD will)
	 (VP (VB be)
	     (VP (VBN observed)
		 (NP (-NONE- *-1))
		 (PP-TMP (IN over)
			 (NP (QP (ADVP (RB at) (RB least))
				 (CD 1.5))
			     (NNS years)))
		 (PP-PRP (IN for)
			 (NP (NP (DT the) (NN occurrence))
			     (PP (IN of)
				 (NP (NP (JJ myocardial) (NN infarction))
				     (CC or)
				     (NP (JJ other) (JJ cardiovascular) (NNS events)))))))))
     (. .)))

( (S (S (PP (IN Unlike)
	    (, ,)
	    (NP (NP (NN MIRACL))
		(CC and)
		(NP (DT the) (NNP A-2-Z) (NNS trials))))
	(, ,)
	(NP-SBJ (DT this) (NN study))
	(VP (MD will)
	    (RB not)
	    (VP (VB assess)
		(NP (NP (DT the) (NN efficacy))
		    (PP (IN of)
			(NP (JJ early) (NN statin) (NN therapy)))
		    (PP (IN after)
			(NP (DT an) (JJ acute) (JJ coronary) (NN syndrome)))))))
     (, ;)
     (S (ADVP (RB rather))
	(, ,)
	(NP-SBJ (PRP it))
	(VP (MD will)
	    (VP (VB examine)
		(NP (NP (DT the) (NN role))
		    (PP (IN of)
			(NP (ADJP (ADVP (RBR more) (CC vs.) (RBR less))
				  (JJ aggressive))
			    (NN lipid)
			    (HYPH -)
			    (NN lowering))))
		(PP (IN in)
		    (NP (DT this) (NN setting))))))
     (. .)))

( (S (PP-TMP (IN In)
	     (NP (NN 2002)))
     (, ,)
     (NP-SBJ (JJ many))
     (VP (MD would)
	 (VP (VB consider)
	     (S (NP-SBJ (NP (PRP it))
			(S (-NONE- *EXP*-1)))
		(ADJP-PRD (JJ unethical))
		(S-1 (NP-SBJ (-NONE- *PRO*))
		     (VP (TO to)
			 (VP (VB withhold)
			     (NP (NNS statins))
			     (PP (IN from)
				 (NP (NP (NNS patients))
				     (PP (IN with)
					 (NP (VBN established) (JJ coronary) (NN disease)))))))))))
     (. .)))

( (S (NP-SBJ (DT This))
     (VP (VBZ makes)
	 (S (NP-SBJ (NP (PRP it))
		    (SBAR (-NONE- *EXP*-1)))
	    (ADJP-PRD (JJ unlikely))
	    (SBAR-1 (IN that)
		    (S (NP-SBJ-2 (JJ additional)
				 (ADJP (NN placebo) (HYPH -) (VBN controlled))
				 (NNS trials))
		       (VP (MD will)
			   (VP (VB be)
			       (VP (VBN carried)
				   (NP (-NONE- *-2))
				   (PRT (RP out))
				   (PP (IN in)
				       (NP (DT this) (NN area))))))))))
     (. .)))

( (S (NP-SBJ-1 (JJ Future) (JJ secondary) (NN prevention) (NNS studies))
     (VP (VP (MD should)
	     (VP (VB look)
		 (PP-CLR (IN at)
			 (NP (NP (NNS patients))
			     (PP (IN with)
				 (NP (ADJP (JJ stable) (CC or) (JJ unstable))
				     (NN disease)))))))
	 (CC and)
	 (VP (MD will)
	     (VP (VB need)
		 (S (NP-SBJ (-NONE- *-1))
		    (VP (TO to)
			(VP (VP (VB address)
				(NP (NP (DT the) (JJ comparative) (NN efficacy))
				    (PP (IN of)
					(NP (NP (JJ different) (NNS statins))
					    (CODE -LRB-)
					    (CC or)
					    (NP (JJR newer) (NNS agents))))))
			    (CODE -RRB-)
			    (, ,)
			    (VP (VB assess)
				(NP (NP (DT the) (JJ incremental) (NN benefit))
				    (PP (IN of)
					(NP (NN combination) (NN therapy)))))
			    (CODE {COM:footnote_indexical_omitted})
			    (CC and)
			    (VP (VB determine)
				(SBAR (IN whether)
				      (S (NP-SBJ (EX there))
					 (VP (VBZ is)
					     (NP-PRD (NP (DT a)
							 (NML (NN serum) (NN cholesterol))
							 ('' ')
							 (NN floor))
						     ('' ')
						     (SBAR (WHPP-2 (IN below)
								   (WHNP (WP which)))
							   (S (NP-SBJ (NNS reductions))
							      (VP (VBP are)
								  (ADJP-PRD (ADJP (JJ unlikely))
									    (S (NP-SBJ (-NONE- *PRO*))
									       (VP (TO to)
										   (VP (VB provide)
										       (NP (JJR further) (JJ clinical) (NN benefit))))))
								  (PP (-NONE- *T*-2))))))))))))))))
     (. .)))

( (NP (VBG Competing) (NNS interests)))

( (S (NP-SBJ (NNP Dr) (NNP Aronow))
     (VP (VBZ has)
	 (VP (VBN received)
	     (NP (FW honoraria))
	     (PP (PP (IN as)
		     (NP (NP (DT a)
			     (NML (NML (NN speaker))
				  (CC and)
				  (NML (NN advisory) (NN board)))
			     (NN member))
			 (PP (IN for)
			     (NP (NNP Pfizer)))))
		 (CC and)
		 (PP (IN as)
		     (NP (NP (DT a) (NN speaker))
			 (PP (IN for)
			     (NP (NNP Merck))))))))
     (. .)))

( (NP (NNS Abbreviations)))

( (CODE {COM:list_omitted}))

